Evidence map›Paper›PMID 40772735›Full record

ArticleBiotechnology progress

Enhancing rapid Protein A performance in monoclonal antibody processing: Anion exchange chromatographic clarification.

Andrew Vail, David Chau, Jennifer Heitkamp, Alexei Voloshin

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew VailPurification and Filtration Business, Solventum, St. Paul, Minnesota, USA.ORCID 0009-0004-3431-6828
David ChauPurification and Filtration Business, Solventum, St. Paul, Minnesota, USA.
Jennifer HeitkampPurification and Filtration Business, Solventum, St. Paul, Minnesota, USA.
Alexei VoloshinPurification and Filtration Business, Solventum, St. Paul, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clarification fidelity, including reduction of insoluble and soluble contaminants, has been demonstrated to significantly affect the performance and robustness of the Protein A capture chromatography step during the purification of monoclonal antibodies (mAb) and their derivatives expressed in CHO cell cultures. While the vast majority of previous studies have focused on the evaluation of these effects on conventional Protein A resins, in this study, we evaluated such effects on the new membrane- and fiber-based Protein A technologies. Both depth filtration and chromatographic clarification using charged functional fiber approaches have been studied, and we evaluated the effects of these methods on convective Protein A technology cycling robustness, as well as the purity of the product in the elution pool with respect to process-related contaminants. We found that clarification of CHO cell culture using anion exchange (AEX) fiber significantly increases the purity of the mAb in the elution pool with respect to host cell protein (at least 50% less) and DNA (>2 log less) as well as enables a higher number of Protein A cycles (at least 2X increase in fiber-based Protein A cycling lifetime) compared to CHO cell culture fluid clarified with conventional depth filtration. It is likely that this is due to superior DNA and sub-500 nm particle reduction during the chromatographic fiber clarification. This work elucidates the importance of a holistic process strategy when designing a biopharmaceutical purification process.

Indexed as

Antibodies, MonoclonalStaphylococcal Protein AAnimalsCHO CellsChromatography, Ion ExchangeCricetinaeCricetulusAntibodies, MonoclonalStaphylococcal Protein Aanion exchangebioprocessingchromatographic clarificationclarificationimpurity reductionProtein A chromatography

Identifiers

PMID40772735
PMCPMC12696437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.